
-
Emergent BioSolutions Inc NYSE:EBS Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Location: 300 Professional Drive, Gaithersburg, MD, 20879, United States | Website: https://www.emergentbiosolutions.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
874.2M
Cash
149.1M
Avg Qtr Burn
N/A
Short % of Float
14.99%
Insider Ownership
2.85%
Institutional Own.
67.25%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NARCAN (naloxone HCl) Details Opioid overdose | Approved Update | |
NARCAN (naloxone HCl) Details Opioid overdose | Approved Quarterly sales | |
ACAM2000 Details Smallpox | Approved Quarterly sales | |
CYFENDUS™ (AV7909 ) Details Anthrax | Approved Quarterly sales | |
Vaxchora (pediatric) Details Cholera | Approved Quarterly sales | |
Approved Quarterly sales | ||
COVID-HIG Details COVID-19 | Failed Discontinued | |
CHIKV VLP Details Chikungunya, Viral infection | Failed Discontinued | |
Stabilized isoamyl nitrite (SIAN) Details Cyanide poisoning | Failed Discontinued | |
FLU-IGIV Details Influenza | Failed Discontinued |